Preliminary study of nanonized lamotrigine containing products for nasal powder formulation

Péter Gieszinger, Ildikó Csóka, Edina Pallagi, Gábor Katona, Orsolya Jójárt-Laczkovich, P. Szabó-Révész, Rita Ambrus

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

The nasal delivery of drugs offers a great alternative route to avoid adverse events and to increase patient compliance due to its advantageous properties. Besides nasal application, topical, systemic and central effects are also available. Nasal powders (NPs) have better adhesion due to the additive polymers that may be, eg, gelling or good wettability agents; thus, their bioavailability is better compared to the liquid formulations. Using nanoparticles, innovative and more efficient products can be achieved, which may lead to the improvement of different therapies. The aim of this study was to produce NP formulations containing lamotrigine (LAM) as interactive physical mixtures and nanosized LAM-based formulations. After risk assessment of the preliminary tests, the micrometric properties (particle size and morphology) and the structural properties (differential scanning calorimetry [DSC], X-ray powder diffraction [XRPD]) were investigated; thereafter, physicochemical properties (solubility, polarity) and in vitro dissolution and diffusion profiles were also examined. These product samples showed an appropriate particle size ranging 10-25 μm, while the particle size of LAM in the products was between 120 and 230 nm and the dissolved amount of drug was >60% after 5 minutes in these cases.

Original languageEnglish
Pages (from-to)2453-2466
Number of pages14
JournalDrug Design, Development and Therapy
Volume11
DOIs
Publication statusPublished - Aug 23 2017

Fingerprint

Nose
Powders
Particle Size
Wettability
Powder Diffraction
Differential Scanning Calorimetry
Patient Compliance
X-Ray Diffraction
Pharmaceutical Preparations
Nanoparticles
Solubility
Biological Availability
Polymers
lamotrigine
Therapeutics

Keywords

  • Co-milling
  • Lamotrigine
  • Nanonization
  • Nasal powder
  • Risk assessment

ASJC Scopus subject areas

  • Pharmacology
  • Pharmaceutical Science
  • Drug Discovery

Cite this

Preliminary study of nanonized lamotrigine containing products for nasal powder formulation. / Gieszinger, Péter; Csóka, Ildikó; Pallagi, Edina; Katona, Gábor; Jójárt-Laczkovich, Orsolya; Szabó-Révész, P.; Ambrus, Rita.

In: Drug Design, Development and Therapy, Vol. 11, 23.08.2017, p. 2453-2466.

Research output: Contribution to journalArticle

Gieszinger, Péter ; Csóka, Ildikó ; Pallagi, Edina ; Katona, Gábor ; Jójárt-Laczkovich, Orsolya ; Szabó-Révész, P. ; Ambrus, Rita. / Preliminary study of nanonized lamotrigine containing products for nasal powder formulation. In: Drug Design, Development and Therapy. 2017 ; Vol. 11. pp. 2453-2466.
@article{087385cd4c8f43a29e9ff9e07cb968f0,
title = "Preliminary study of nanonized lamotrigine containing products for nasal powder formulation",
abstract = "The nasal delivery of drugs offers a great alternative route to avoid adverse events and to increase patient compliance due to its advantageous properties. Besides nasal application, topical, systemic and central effects are also available. Nasal powders (NPs) have better adhesion due to the additive polymers that may be, eg, gelling or good wettability agents; thus, their bioavailability is better compared to the liquid formulations. Using nanoparticles, innovative and more efficient products can be achieved, which may lead to the improvement of different therapies. The aim of this study was to produce NP formulations containing lamotrigine (LAM) as interactive physical mixtures and nanosized LAM-based formulations. After risk assessment of the preliminary tests, the micrometric properties (particle size and morphology) and the structural properties (differential scanning calorimetry [DSC], X-ray powder diffraction [XRPD]) were investigated; thereafter, physicochemical properties (solubility, polarity) and in vitro dissolution and diffusion profiles were also examined. These product samples showed an appropriate particle size ranging 10-25 μm, while the particle size of LAM in the products was between 120 and 230 nm and the dissolved amount of drug was >60{\%} after 5 minutes in these cases.",
keywords = "Co-milling, Lamotrigine, Nanonization, Nasal powder, Risk assessment",
author = "P{\'e}ter Gieszinger and Ildik{\'o} Cs{\'o}ka and Edina Pallagi and G{\'a}bor Katona and Orsolya J{\'o}j{\'a}rt-Laczkovich and P. Szab{\'o}-R{\'e}v{\'e}sz and Rita Ambrus",
year = "2017",
month = "8",
day = "23",
doi = "10.2147/DDDT.S138559",
language = "English",
volume = "11",
pages = "2453--2466",
journal = "Drug Design, Development and Therapy",
issn = "1177-8881",
publisher = "Dove Medical Press Ltd.",

}

TY - JOUR

T1 - Preliminary study of nanonized lamotrigine containing products for nasal powder formulation

AU - Gieszinger, Péter

AU - Csóka, Ildikó

AU - Pallagi, Edina

AU - Katona, Gábor

AU - Jójárt-Laczkovich, Orsolya

AU - Szabó-Révész, P.

AU - Ambrus, Rita

PY - 2017/8/23

Y1 - 2017/8/23

N2 - The nasal delivery of drugs offers a great alternative route to avoid adverse events and to increase patient compliance due to its advantageous properties. Besides nasal application, topical, systemic and central effects are also available. Nasal powders (NPs) have better adhesion due to the additive polymers that may be, eg, gelling or good wettability agents; thus, their bioavailability is better compared to the liquid formulations. Using nanoparticles, innovative and more efficient products can be achieved, which may lead to the improvement of different therapies. The aim of this study was to produce NP formulations containing lamotrigine (LAM) as interactive physical mixtures and nanosized LAM-based formulations. After risk assessment of the preliminary tests, the micrometric properties (particle size and morphology) and the structural properties (differential scanning calorimetry [DSC], X-ray powder diffraction [XRPD]) were investigated; thereafter, physicochemical properties (solubility, polarity) and in vitro dissolution and diffusion profiles were also examined. These product samples showed an appropriate particle size ranging 10-25 μm, while the particle size of LAM in the products was between 120 and 230 nm and the dissolved amount of drug was >60% after 5 minutes in these cases.

AB - The nasal delivery of drugs offers a great alternative route to avoid adverse events and to increase patient compliance due to its advantageous properties. Besides nasal application, topical, systemic and central effects are also available. Nasal powders (NPs) have better adhesion due to the additive polymers that may be, eg, gelling or good wettability agents; thus, their bioavailability is better compared to the liquid formulations. Using nanoparticles, innovative and more efficient products can be achieved, which may lead to the improvement of different therapies. The aim of this study was to produce NP formulations containing lamotrigine (LAM) as interactive physical mixtures and nanosized LAM-based formulations. After risk assessment of the preliminary tests, the micrometric properties (particle size and morphology) and the structural properties (differential scanning calorimetry [DSC], X-ray powder diffraction [XRPD]) were investigated; thereafter, physicochemical properties (solubility, polarity) and in vitro dissolution and diffusion profiles were also examined. These product samples showed an appropriate particle size ranging 10-25 μm, while the particle size of LAM in the products was between 120 and 230 nm and the dissolved amount of drug was >60% after 5 minutes in these cases.

KW - Co-milling

KW - Lamotrigine

KW - Nanonization

KW - Nasal powder

KW - Risk assessment

UR - http://www.scopus.com/inward/record.url?scp=85028641656&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85028641656&partnerID=8YFLogxK

U2 - 10.2147/DDDT.S138559

DO - 10.2147/DDDT.S138559

M3 - Article

VL - 11

SP - 2453

EP - 2466

JO - Drug Design, Development and Therapy

JF - Drug Design, Development and Therapy

SN - 1177-8881

ER -